Neurofilament Light Chain (Nfl) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurofilament light chain (NfL) is a 68 kDa cytoskeletal protein and a major structural component of neuronal intermediate filaments, which are critical for maintaining axonal caliber and facilitating efficient nerve impulse conduction. [NfL[/entities/neurofilament-light is one of three neurofilament subunits (light, medium, and heavy), encoded by the [NEFL[/genes/nefl gene on chromosome 8p21. [When [neurons[/entities/neurons are damaged or destroyed — regardless of the underlying cause — [NfL[/entities/neurofilament-light is released into the extracellular space, [cerebrospinal fluid[/diagnostics/csf-biomarkers (CSF), and subsequently into blood, making it one of the most widely validated [biomarkers] of neuroaxonal injury across the spectrum of neurodegenerative diseases ([Khalil et al., 2018]https://doi.org/10.1038/s41582-018-0058-z)).
[NfL[/entities/neurofilament-light has emerged as a pivotal fluid biomarker in clinical trials and diagnostics for [Alzheimer's disease[/diseases/alzheimers, [Parkinson's disease[/diseases/parkinsons, [ALS[/diseases/als, [Huntington's disease[/mechanisms/huntington-pathway, [multiple sclerosis[/diseases/multiple-sclerosis, [frontotemporal dementia[/diseases/ftd, and many other neurological conditions. The FDA's 2023 approval of [tofersen[/treatments/tofersen for SOD1-ALS, based in part on [NfL[/entities/neurofilament-light reduction as a surrogate endpoint, marked a milestone for [NfL[/entities/neurofilament-light's clinical utility (Miller et al., 2022).
Neurofilaments are type IV intermediate filaments found exclusively in [neurons[/entities/neurons. They consist of three subunit proteins that co-assemble into heteropolymers:
NfL is obligatory for neurofilament assembly — without it, NfM and NfH cannot polymerize. Neurofilaments interact with [microtubules[/entities/microtubules and actin filaments to form the axonal cytoskeleton, which is essential for:
In healthy [neurons[/entities/neurons, NfL has a very long half-life (months to years) and is slowly degraded within axons. Under normal conditions, minimal NfL is released into the extracellular space, resulting in low baseline CSF and blood concentrations. CSF NfL levels in healthy adults typically range from 100-800 pg/mL, while plasma NfL levels are approximately 40-fold lower (5-35 pg/mL), increasing modestly with age (Bridel et al., 2019).
When [neurons[/entities/neurons undergo injury — from [neurodegeneration], inflammation, trauma, or other insults — neurofilaments are released from damaged axons into the interstitial fluid. NfL then enters the CSF by diffusion across the brain parenchyma and subsequently reaches the blood by crossing the [blood-brain barrier[/entities/blood-brain-barrier or through CSF absorption into the venous system. The blood NfL concentration is proportional to the rate and extent of neuroaxonal damage, though with a time lag of days to weeks relative to the initial injury.
NfL is elevated in virtually every condition involving neuroaxonal damage:
| Disease | Typical CSF NfL (pg/mL) | Clinical Utility |
|---|---|---|
| [Alzheimer's disease[/diseases/alzheimers | 1,000-3,000 | Correlates with neurodegeneration severity, predicts cognitive decline; elevated years before symptom onset in autosomal dominant AD |
| [ALS[/diseases/als | 3,000-20,000+ | Among highest levels; correlates with disease progression rate; used as surrogate endpoint for tofersen |
| [FTD[/diseases/ftd | 2,000-10,000 | Differentiates from psychiatric disorders; predicts survival |
| [Huntington's disease[/mechanisms/huntington-pathway | 800-4,000 | Correlates with disease stage; elevated in premanifest carriers |
| [multiple sclerosis[/diseases/multiple-sclerosis | 500-3,000 | Reflects acute axonal damage; monitors treatment response |
| [Parkinson's disease[/diseases/parkinsons | 500-1,500 | Modestly elevated; helps differentiate from atypical parkinsonism |
| [CJD/Prion Disease] | 5,000-50,000+ | Extremely high; rapidly progressive neurodegeneration |
The development of ultrasensitive single-molecule array (Simoa) immunoassay technology has enabled reliable quantification of NfL in blood plasma, transforming it from a CSF-only to a blood-based biomarker. Plasma NfL correlates well with CSF NfL (r=0.70-0.85) and has been validated in large cohort studies (Mattsson et al., 2017). This is particularly significant because blood sampling is minimally invasive compared to lumbar puncture, enabling:
Despite its clinical value, NfL has important limitations:
NfL has been incorporated as an endpoint in over 100 clinical trials as of 2025:
NfL complements other neurodegenerative biomarkers:
The study of Neurofilament Light Chain (Nfl) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.